These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 8527411)

  • 1. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
    Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
    Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor and antimetastatic effects of interleukin 12.
    Fujiwara H; Hamaoka T
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S22-6. PubMed ID: 8765411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
    Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production.
    Fujiwara H; Hamaoka T
    Leukemia; 1997 Apr; 11 Suppl 3():570-1. PubMed ID: 9209457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
    Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
    Yu WG; Ogawa M; Mu J; Umehara K; Tsujimura T; Fujiwara H; Hamaoka T
    J Leukoc Biol; 1997 Oct; 62(4):450-7. PubMed ID: 9335314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
    Yu WG; Yamamoto N; Takenaka H; Mu J; Tai XG; Zou JP; Ogawa M; Tsutsui T; Wijesuriya R; Yoshida R; Herrmann S; Fujiwara H; Hamaoka T
    Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
    Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
    J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state.
    Wijesuriya R; Maruo S; Zou JP; Ogawa M; Umehara K; Yamashita M; Ono S; Fujiwara H; Hamaoka T
    Int Immunol; 1998 Aug; 10(8):1057-65. PubMed ID: 9723691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo recovery of IFN-gamma, but not IL-2, production by IL-12 in mice with plasma cell tumors.
    Ruzek MC; Mathur A
    Int Immunol; 1996 Mar; 8(3):413-22. PubMed ID: 8671628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.
    Ahn HJ; Maruo S; Tomura M; Mu J; Hamaoka T; Nakanishi K; Clark S; Kurimoto M; Okamura H; Fujiwara H
    J Immunol; 1997 Sep; 159(5):2125-31. PubMed ID: 9278298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
    Taniguchi F; Yamagishi H; Fujiwara H; Ueda Y; Fuji N; Yoshimura T; Oka T
    Gene Ther; 1998 Dec; 5(12):1677-84. PubMed ID: 10023447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
    Iwasaki M; Yu WG; Uekusa Y; Nakajima C; Yang YF; Gao P; Wijesuriya R; Fujiwara H; Hamaoka T
    Int Immunol; 2000 May; 12(5):701-9. PubMed ID: 10784616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
    Bohn E; Autenrieth IB
    J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exogenous interleukin-3 enhances IL-4 production by splenic CD4+ cells during the early stages of a Trichinella spiralis infection.
    Korenaga M; Akimaru Y; Hashiguchi Y
    Int Arch Allergy Immunol; 1998 Oct; 117(2):131-7. PubMed ID: 9784657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-28 elicits antitumor responses against murine fibrosarcoma.
    Numasaki M; Tagawa M; Iwata F; Suzuki T; Nakamura A; Okada M; Iwakura Y; Aiba S; Yamaya M
    J Immunol; 2007 Apr; 178(8):5086-98. PubMed ID: 17404291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis.
    Mizuhara H; Uno M; Seki N; Yamashita M; Yamaoka M; Ogawa T; Kaneda K; Fujii T; Senoh H; Fujiwara H
    Hepatology; 1996 Jun; 23(6):1608-15. PubMed ID: 8675184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.